Climbazole
- CAS
- 38083-17-9
- EC
- 2537754
- PubChem CID
- 37907
- Molecular Formula
- C15H17ClN2O2
- Molecular Weight
- 292.7600 g/mol
Anti-dandruff agent. Its concentration in products is limited as it may cause skin irritation.
What does it do?
An anti-dandruff and antifungal agent.
Details
An active ingredient that is anti-dandruff and antifungal. It kills fungal cells by disrupting the cell membranes of bacteria; however, if it contacts the sensitive layers of the skin, it can cause irritation, dryness, and even scaling, creating an irony where the situation may worsen after getting rid of dandruff.
Benefits
Functions
Restrictions
Where is it found?
Function & Use
Antimicrobial
Preservative
Regulatory note
- EU 1223/2009 Annex IIIRestricted
Maximum concentration: 2%
- EU 1223/2009 Annex VAllowed
Industry GHS notices (PubChem)
These are industry self-reports to ECHA, not our regulatory assessment.
- H302(99.5%)- Harmful if swallowed
- H400(62.5%)- Very toxic to aquatic life
- H410(69.5%)- Very toxic to aquatic life with long lasting effects
- H412(26.0%)- Harmful to aquatic life with long lasting effects
What The Sources Say
SCCS (EU Scientific Committee on Consumer Safety)10
EU 1223/2009 Annex III — SCCS opinion: Opinion concerning Azole Antimycotic Resistance
EU 1223/2009 Annex III — SCCS opinion: Opinion on Climbazole
EU 1223/2009 Annex III — SCCS opinion: ADDENDUM to the scientific Opinions on Climbazole (P64) ref. SCCS/1506/13 and SCCS/1590/17
EU 1223/2009 Annex V — SCCS opinion: Opinion concerning Restrictions on Materials listed in annex VI of Directive 76/768/EEC on Cosmetic Products
EU 1223/2009 Annex V — SCCS opinion: Opinion concerning Azole Antimycotic Resistance
+5 more records.
Europe PMC (scientific literature)1
Cited by 43. Background Endocrine-disrupting chemicals can interfere with hormonal homeostasis and have adverse effects for both humans and the environment. Their identification is increasingly difficult due to lack of adequate toxicological tests. This difficulty is particularly problematic for cosmetic ingredients, because in vivo testing is now banned completely in the European Union. Objectives The aim was
ToxValDB (EPA Toxicity Value Database)6
EPA ToxValDB skin/eye data — endpoint: skin corrosion: in vitro / ex vivo, classification: Studies Indicate No Significant Irritation, study: skin irritation, guideline: other guideline: According to Human Skin Model Test EU-Method B.46 adopted 23. July 2009 according to, year: 2010. Caveat: this is an aggregated record; dose, species and route of exposure must be considered together.
EPA ToxValDB skin/eye data — endpoint: skin sensitisation: in vivo (non-LLNA), classification: Not likely to be sensitizing, species: guinea pig, study: skin sensitization, guideline: according to other guideline: former version of EU Method B.6 (Skin Sensitisation): EEC 79/831, Appendix V, Part B, 4.1.7. Skin Sensitization, year: 1983. Caveat: this is an aggregated record; dose, species and route of exposure must be considered together.
EPA ToxValDB skin/eye data — endpoint: eye irritation: in vitro / ex vivo, classification: Studies Indicate No Significant Irritation, study: eye irritation, guideline: other guideline: INVITTOX Protocol No. 47: HET-CAM Test according to, year: 2007. Caveat: this is an aggregated record; dose, species and route of exposure must be considered together.
EPA ToxValDB skin/eye data — endpoint: eye irritation: in vivo, classification: Ambiguous, species: rabbit, study: eye irritation, guideline: other guideline: The investigations were carried out in compliance with the recommendations of the Department of Health, Education and Welfare (Hazardous Substances, Test for Eye Irritants, Federal Register 37, 8534, 1972). according to, year: 1975. Caveat: this is an aggregated record; dose, species and route of exposure must be considered together.
EPA ToxValDB skin/eye data — endpoint: skin sensitisation: in vivo (LLNA), classification: Ambiguous, species: mouse, study: skin sensitization, guideline: according to OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay) according to EPA OPPTS 870.2600 (Skin Sensitisation), year: 2007. Caveat: this is an aggregated record; dose, species and route of exposure must be considered together.
+1 more records.
Scientific References
- ADDENDUM to the scientific Opinions on Climbazole (P64) ref. SCCS/1506/13 and SCCS/1590/17SCCS — Scientific Committee on Consumer Safety
- EPA CompTox Chemicals Dashboard — DSSTox identifiers mapped to CAS (2021r1)US EPA, Center for Computational Toxicology and Exposure
- EU CosIng — Cosmetic Ingredient Database full exportEuropean Commission, DG GROW
- OpenFDA Cosmetic Adverse Events (api.fda.gov/cosmetic/event)US FDA — unvalidated adverse event reports
- Opinion concerning Azole Antimycotic ResistanceSCCS — Scientific Committee on Consumer Safety
- Opinion concerning Restrictions on Materials listed in annex VI of Directive 76/768/EEC on Cosmetic ProductsSCCS — Scientific Committee on Consumer Safety
- Opinion on ClimbazoleSCCS — Scientific Committee on Consumer Safety
- PubChem — CID-Synonym-filtered bulk + PUG REST propertiesNCBI / National Library of Medicine
- ToxValDB — genotoxicityUS EPA — ToxValDB v97
- ToxValDB — skin/eyeUS EPA — ToxValDB v97
- Triclocarban, Triclosan, Bromochlorophene, Chlorophene, and Climbazole Effects on Nuclear Receptors: An in Silico and in Vitro Study.Environmental health perspectives